Prostate-specific antigen (PSA)-based screening has not been shown to reduce prostate cancer–specific mortality, but is associated with harms related to subsequent evaluation and treatments, some of which may be unnecessary, according to a new analysis of the evidence by the US Preventive Services Task Force (USPSTF) published online in the Annals of Internal Medicine. The new guidelines will downgrade PSA screening from “I—inconclusive” to “D—no benefit” for men younger than 75, basically stating that younger, healthy men should not undergo this testing. The Prostate Cancer Foundation and the American Cancer Society continue to support better communication and processes of informed patient decision-making prior to, and after, PSA screening in healthy men
